Association of preoperative plasma endoglin levels with clinical and pathologic features of 425 patients treated with radical prostatectomy and bilateral lymphadenectomy for clinically localized prostate cancer
| . | No. (%) . | Median plasma endoglin level, ng/mL (IQR) . | P . | |||
|---|---|---|---|---|---|---|
| Total (%) | 425 (100) | 28.8 (18.7-37.5) | — | |||
| Clinical stage | ||||||
| T1 | 269 (63.3) | 28.6 (19.3-36.3) | — | |||
| T2 | 156 (36.7) | 29.4 (18.0-39.8) | 0.19* | |||
| Extraprostatic extension† | ||||||
| Negative | 282 (67.0) | 28.2 (19.3-35.8) | — | |||
| Positive | 139 (33.0) | 30.6 (15.1-40.9) | 0.21* | |||
| Seminal vesicle involvement† | ||||||
| Negative | 354 (84.1) | 28.3 (19.3-36.1) | — | |||
| Positive | 67 (15.9) | 31.3 (13.9-45.0) | 0.20* | |||
| Surgical margin status† | ||||||
| Negative | 331 (78.6) | 28.0 (18.6-36.0) | — | |||
| Positive | 90 (21.4) | 31.9 (18.5-43.9) | 0.03* | |||
| Biopsy Gleason sum‡ | ||||||
| 2-6 | 292 (70.0) | 27.9 (19.2-35.9) | — | |||
| 7 | 93 (22.3) | 31.2 (18.3-39.8) | — | |||
| 8-10 | 32 (7.7) | 36.1 (14.1-51.4) | 0.10§ | |||
| Pathologic Gleason sum† | ||||||
| 2-6 | 199 (47.2) | 27.3 (18.8-35.4) | — | |||
| 7 | 180 (42.8) | 28.7 (18.6-38.3) | — | |||
| 8-10 | 42 (10.0) | 33.8 (17.2-49.2) | 0.04§ | |||
| Lymphovascular invasion∥ | ||||||
| Negative | 222 (88.8) | 26.5 (18.1-33.3) | — | |||
| Positive | 28 (11.2) | 25.2 (13.8-53.9) | 0.40* | |||
| Perineural invasion∥ | ||||||
| Negative | 94 (37.6) | 24.4 (17.5-32.8) | — | |||
| Positive | 156 (62.4) | 27.4 (17.9-35.8) | 0.14* | |||
| Lymph node metastases¶ | ||||||
| Negative | 408 (96.7) | 27.9 (18.3-36.3) | ||||
| Positive | 14 (3.3) | 57.1 (51.4-67.3) | <0.001* | |||
| . | No. (%) . | Median plasma endoglin level, ng/mL (IQR) . | P . | |||
|---|---|---|---|---|---|---|
| Total (%) | 425 (100) | 28.8 (18.7-37.5) | — | |||
| Clinical stage | ||||||
| T1 | 269 (63.3) | 28.6 (19.3-36.3) | — | |||
| T2 | 156 (36.7) | 29.4 (18.0-39.8) | 0.19* | |||
| Extraprostatic extension† | ||||||
| Negative | 282 (67.0) | 28.2 (19.3-35.8) | — | |||
| Positive | 139 (33.0) | 30.6 (15.1-40.9) | 0.21* | |||
| Seminal vesicle involvement† | ||||||
| Negative | 354 (84.1) | 28.3 (19.3-36.1) | — | |||
| Positive | 67 (15.9) | 31.3 (13.9-45.0) | 0.20* | |||
| Surgical margin status† | ||||||
| Negative | 331 (78.6) | 28.0 (18.6-36.0) | — | |||
| Positive | 90 (21.4) | 31.9 (18.5-43.9) | 0.03* | |||
| Biopsy Gleason sum‡ | ||||||
| 2-6 | 292 (70.0) | 27.9 (19.2-35.9) | — | |||
| 7 | 93 (22.3) | 31.2 (18.3-39.8) | — | |||
| 8-10 | 32 (7.7) | 36.1 (14.1-51.4) | 0.10§ | |||
| Pathologic Gleason sum† | ||||||
| 2-6 | 199 (47.2) | 27.3 (18.8-35.4) | — | |||
| 7 | 180 (42.8) | 28.7 (18.6-38.3) | — | |||
| 8-10 | 42 (10.0) | 33.8 (17.2-49.2) | 0.04§ | |||
| Lymphovascular invasion∥ | ||||||
| Negative | 222 (88.8) | 26.5 (18.1-33.3) | — | |||
| Positive | 28 (11.2) | 25.2 (13.8-53.9) | 0.40* | |||
| Perineural invasion∥ | ||||||
| Negative | 94 (37.6) | 24.4 (17.5-32.8) | — | |||
| Positive | 156 (62.4) | 27.4 (17.9-35.8) | 0.14* | |||
| Lymph node metastases¶ | ||||||
| Negative | 408 (96.7) | 27.9 (18.3-36.3) | ||||
| Positive | 14 (3.3) | 57.1 (51.4-67.3) | <0.001* | |||
P value calculated from Mann-Whitney U test.
Data on extraprostatic extension, seminal vesicle invasion, surgical margin status, and pathologic Gleason sum were not available in four patients.
Biopsy Gleason sum was not available in eight patients.
P value calculated from Kruskal-Wallis test.
Data on lymphovascular and perineural invasion were not available in 175 patients.
Lymph node status was not available in three patients.